English Polski
Tom 3, Nr 4 (2010)
Artykuł przeglądowy
Opublikowany online: 2010-12-29

dostęp otwarty

Wyświetlenia strony 937
Wyświetlenia/pobrania artykułu 6610
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Aktualny stan i perspektywy nieinwazyjnej diagnostyki prenatalnej w konfliktach matczyno-płodowych

Katarzyna Guz, Agnieszka Orzińska, Izabella Kopeć, Magdalena Krzemienowska, Justyna Smolarczyk-Wodzyńska, Ewa Brojer
Journal of Transfusion Medicine 2010;3(4):144-154.

Streszczenie

Nieinwazyjna diagnostyka prenatalna jest oparta na analizie pozakomórkowego DNA płodu obecnego w osoczu kobiet w ciąży. W niniejszej pracy poglądowej autorki przeanalizowały przyczyny stosowania obecnie tej metodologii tylko do genotypowania niektórych antygenów krwinek czerwonych płodu. Podsumowały też doświadczenia Instytutu Hematologii i Transfuzjologii w prenatalnej diagnostyce konfliktów matczyno-płodowych w zakresie antygenów RhD, RhC+D, Rhc, RhE i K oraz omówiły perspektywy rozwoju badań prenatalnych na podstawie nowoczesnych technologii: digital PCR, spektrometrii mas MALDI-TOF, sekwencjonowania nowej generacji.

J. Transf. Med. 2010; 4: 144–154

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997; 350(9076): 485–487.
  2. Lo YM, Tein MS, Lau TK, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet. 1998; 62(4): 768–775.
  3. Lo YM, Zhang J, Leung TN, et al. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet. 1999; 64(1): 218–224.
  4. Bianchi DW, Zickwolf GK, Weil GJ, et al. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc Natl Acad Sci U S A. 1996; 93(2): 705–708.
  5. Lo YM, Hjelm NM, Fidler C, et al. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med. 1998; 339(24): 1734–1738.
  6. Costa JM, Benachi A, Gautier E. New strategy for prenatal diagnosis of X-linked disorders. N Engl J Med. 2002; 346(19): 1502.
  7. Avent ND, Madgett TE, Maddocks DG, et al. Cell-free fetal DNA in the maternal serum and plasma: current and evolving applications. Curr Opin Obstet Gynecol. 2009; 21(2): 175–179.
  8. Chen CP, Chern SR, Wang W. Fetal DNA in maternal plasma: the prenatal detection of a paternally inherited fetal aneuploidy. Prenat Diagn. 2000; 20(4): 355–357.
  9. Engel K, Płonka T, Bilar M, et al. The correlation between clinical characteristics of preeclampsia and the concentration of fetal DNA in maternal circulation. Eur J Obstet Gynecol Reprod Biol. 2008; 139(2): 256–257.
  10. Zimmermann BG, Grill S, Holzgreve W, et al. Digital PCR: a powerful new tool for noninvasive prenatal diagnosis? Prenat Diagn. 2008; 28(12): 1087–1093.
  11. Zhong XY, Holzgreve W. MALDI-TOF MS in Prenatal Genomics. Transfus Med Hemother. 2009; 36(4): 263–272.
  12. Fan HC, Blumenfeld YJ, Chitkara U, et al. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci U S A. 2008; 105(42): 16266–16271.
  13. Brojer E, Zupanska B, Guz K, et al. Noninvasive determination of fetal RHD status by examination of cell-free DNA in maternal plasma. Transfusion. 2005; 45(9): 1473–1480.
  14. Orzińska A, Guz K, Brojer E, et al. Preliminary results of fetal Rhc examination in plasma of pregnant women with anti-c. Prenat Diagn. 2008; 28(4): 335–337.
  15. Orzińska A, Guz K, Brojer E. Nieinwazyjne badania prenatalne z osocza kobiet ciężarnych w konfliktach serologicznych w sce. Gin Pol. 2009; 80: 768–771.
  16. Murray JC, Karp LE, Williamson RA, et al. Rh isoimmunization related to amniocentesis. Am J Med Genet. 1983; 16(4): 527–534.
  17. Żupańska B, Nowaczek-Migas M, Michalik M, et al. Czy należy wykonywać badania przesiewowe u wszystkich ciężarnych w celu wykrycia przeciwciał innych niż anty-D? Gin. po Dypl. 2009; 2: 38–40.
  18. Lenkiewicz B. Konflikt Rh po 25 latach stosowania immunoprofilaktyki. Gin Pol. 2000; 71: 863–868.
  19. Daniels G. Human blood group. Wyd. 2. Blackwell Science, Oxford 2002.
  20. van der Schoot C.E. Molecular genotyping in prenatal, donor and pre-transfusion testing. www.ortho-wire.com (08.09.2010).
  21. Finning K, Martin P, Summers J, et al. Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. BMJ. 2008; 336(7648): 816–818.
  22. Bussel J. Diagnosis and management of the fetus and neonate with alloimmune thrombocytopenia. J Thromb Haemost. 2009; 7 Suppl 1: 253–257.
  23. Kaplan C. Neonatal alloimmune thrombocytopenia. Haematologica. 2008; 93(6): 805–807.
  24. Paridaans NP, Kamphuis MM, Taune Wikman A, et al. Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic review. BJOG. 2010; 117(11): 1335–1343.
  25. Maslanka K, Guz K, Zupanska B. Antenatal screening of unselected pregnant women for HPA-1a antigen, antibody and alloimmune thrombocytopenia. Vox Sang. 2003; 85(4): 326–327.
  26. Dmochowska H. Rocznik demograficzny 2009. Zakład Wydawnictw Statystycznych, Warszawa 2009: 254.
  27. Orzińska A, Guz K, Gala K, et al. Wpływ warunków pobierania i przechowywania materiału oraz izolacji DNA na wyniki wykrywania genów płodu w osoczu kobiet ciężarnych w celu nieinwazyjnych badań prenatalnych. Diagn Lab. 2007; 43: 69–77.
  28. Fernando MR, Chen K, Norton S, et al. A new methodology to preserve the original proportion and integrity of cell-free fetal DNA in maternal plasma during sample processing and storage. Prenat Diagn. 2010; 30(5): 418–424.
  29. Legler TJ. Prenatal rhesus testing. ISBT Science Series. 2010; 5(n1): 7–11.
  30. Clausen FB, Krog GR, Rieneck K, et al. Improvement in fetal DNA extraction from maternal plasma. Evaluation of the NucliSens Magnetic Extraction system and the QIAamp DSP Virus Kit in comparison with the QIAamp DNA Blood Mini Kit. Prenat Diagn. 2007; 27(1): 6–10.
  31. Legler TJ, Liu Z, Heermann KH, et al. Specific magnetic bead-based capture of free fetal DNA from maternal plasma. Transfus Apher Sci. 2009; 40(3): 153–157.
  32. Flegel WA, von Zabern I, Wagner FF. Six years' experience performing RHD genotyping to confirm D- red blood cell units in Germany for preventing anti-D immunizations. Transfusion. 2009; 49(3): 465–471.
  33. Polin H, Danzer M, Gaszner W, et al. Identification of RHD alleles with the potential of anti-D immunization among seemingly D- blood donors in Upper Austria. Transfusion. 2009; 49(4): 676–681.
  34. Pelc-Kłopotowska M, Orzińska A, Michalewska B, et al. Badanie obecności fragmentów genu RHD u dawców RhD-ujemnych z zastosowaniem minipulowania i technologii real-time PCR. J Transfus Med. 2008; 1: 40–45.
  35. Daniels G, Finning K, Martin P, et al. Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects. Prenat Diagn. 2009; 29(2): 101–107.
  36. Hromadnikova I, Vechetova L, Vesela K, et al. Non-invasive fetal RHD and RHCE genotyping using real-time PCR testing of maternal plasma in RhD-negative pregnancies. J Histochem Cytochem. 2005; 53(3): 301–305.
  37. Gautier E, Benachi A, Giovangrandi Y, et al. Fetal RhD genotyping by maternal serum analysis: a two-year experience. Am J Obstet Gynecol. 2005; 192(3): 666–669.
  38. Hromadnikova I, Vechetova L, Vesela K, et al. Non-invasive fetal RHD exon 7 and exon 10 genotyping using real-time PCR testing of fetal DNA in maternal plasma. Fetal Diagn Ther. 2005; 20(4): 275–280.
  39. González-González C, Garcia-Hoyos M, Trujillo-Tiebas MJ, et al. Application of fetal DNA detection in maternal plasma: a prenatal diagnosis unit experience. J Histochem Cytochem. 2005; 53(3): 307–314.
  40. Zhou L, Thorson JA, Nugent C, et al. Noninvasive prenatal RHD genotyping by real-time polymerase chain reaction using plasma from D-negative pregnant women. Am J Obstet Gynecol. 2005; 193(6): 1966–1971.
  41. Clausen FB, Krog GR, Rieneck K, et al. Reliable test for prenatal prediction of fetal RhD type using maternal plasma from RhD negative women. Prenat Diagn. 2005; 25(11): 1040–1044.
  42. Grootkerk-Tax MG, Soussan AA, de Haas M, et al. Evaluation of prenatal RHD typing strategies on cell-free fetal DNA from maternal plasma. Transfusion. 2006; 46(12): 2142–2148.
  43. Machado IN, Castilho L, Pellegrino J, et al. Fetal rhd genotyping from maternal plasma in a population with a highly diverse ethnic background. Rev Assoc Med Bras (1992). 2006; 52(4): 232–235.
  44. Daniels G, Finning K, Martin P, et al. Fetal blood group genotyping: present and future. Ann N Y Acad Sci. 2006; 1075: 88–95.
  45. Chan KC, Ding C, Gerovassili A, et al. Hypermethylated RASSF1A in maternal plasma: A universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clin Chem. 2006; 52(12): 2211–2218.
  46. Van der Schoot CE, Soussan AA, Koelewijn J, et al. Non-invasive antenatal RHD typing. Transfus Clin Biol. 2006; 13(1-2): 53–57.
  47. Minon JM, Gerard C, Senterre JM, et al. Routine fetal RHD genotyping with maternal plasma: a four-year experience in Belgium. Transfusion. 2008; 48(2): 373–381.
  48. Rouillac-Le Sciellour C, Sérazin V, Brossard Y, et al. Noninvasive fetal RHD genotyping from maternal plasma. Use of a new developed Free DNA Fetal Kit RhD. Transfus Clin Biol. 2007; 14(6): 572–577.
  49. Finning K, Martin P, Summers J, et al. Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma. Transfusion. 2007; 47(11): 2126–2133.
  50. Li Y, Finning K, Daniels G, et al. Noninvasive genotyping fetal Kell blood group (KEL1) using cell-free fetal DNA in maternal plasma by MALDI-TOF mass spectrometry. Prenat Diagn. 2008; 28(3): 203–208.
  51. Kimura M, Sato C, Hara M, et al. Noninvasive fetal RHD genotyping by maternal plasma with capillary electrophoresis. Transfusion. 2008; 48(6): 1156–1163.
  52. Wang XD, Wang BL, Ye SL, et al. Non-invasive foetal RHD genotyping via real-time PCR of foetal DNA from Chinese RhD-negative maternal plasma. Eur J Clin Invest. 2009; 39(7): 607–617.
  53. Hyland CA, Gardener GJ, Davies H, et al. Evaluation of non-invasive prenatal RHD genotyping of the fetus. Med J Aust. 2009; 191(1): 21–25.
  54. Chinen PA, Nardozza LM, Martinhago CD, et al. Noninvasive determination of fetal rh blood group, D antigen status by cell-free DNA analysis in maternal plasma: experience in a Brazilian population. Am J Perinatol. 2010; 27(10): 759–762.
  55. Mohammed N, Kakal F, Somani M, et al. Non-invasive prenatal determination of fetal RhD genotyping from maternal plasma: a preliminary study in Pakistan. J Coll Physicians Surg Pak. 2010; 20(4): 246–249.
  56. Cardo L, García BP, Alvarez FV. Non-invasive fetal RHD genotyping in the first trimester of pregnancy. Clin Chem Lab Med. 2010; 48(8): 1121–1126.
  57. Scheffer P, de Ha, van de, et al. Non-invasive feal blood group genotyping with DNA from maternal plasma: a seven-year clinical experience. Vox Sang. 2010; 99(supl. 1): 25.
  58. Amaral DR, Castillo L. Fetal RHD genotyping by analysis of maternal plasma in a mixed population. Vox Sang. 2010; 99(supl. 1): 25.
  59. Wikman A, Tiblad E, Karlsson A, et al. Detection of fetal RHD DNA in maternal plasma in early pregnancy in an antenatal screening program. Vox Sang. 2010; 99(supl. 1): 25–26.
  60. Orzińska A, Engel K, Łakomy M, et al. [RHD variant in RhD/-/ mother with anti-D makes noninvasive fetal RHD genotyping impossible]. Ginekol Pol. 2009; 80(10): 786–790.
  61. Legler TJ, Lynen R, Maas JH, et al. Prediction of fetal Rh D and Rh CcEe phenotype from maternal plasma with real-time polymerase chain reaction. Transfus Apher Sci. 2002; 27(3): 217–223.
  62. Scheffer P, de Ha, Oepkes D, et al. van der Schoot C. Noninvasive fetal genotyping of 154 Journal of Transfusion Medicine 2010, tom 3, nr 4 www.jtm.viamedica.pl human platelet antigen HPA 1a using cell-free fetal DNA isolated from maternal blood. Vox Sang. 2010; 99(supl. 1): 73.
  63. Wong FCK, Sun K, Jiang P, et al. Size distributions of maternal and fetal DNA in maternal plasma. Clin Chem. 2004; 50(1): 88–92.
  64. Li Y, Zimmermann B, Rusterholz C, et al. Size separation of circulatory DNA in maternal plasma permits ready detection of fetal DNA polymorphisms. Clin Chem. 2004; 50(6): 1002–1011.
  65. Bischoff FZ, Lewis DE, Simpson JL. Cell-free fetal DNA in maternal blood: kinetics, source and structure. Hum Reprod Update. 2005; 11(1): 59–67.
  66. Hromadnikova I, Zejskova L, Doucha J, et al. Quantification of fetal and total circulatory DNA in maternal plasma samples before and after size fractionation by agarose gel electrophoresis. DNA Cell Biol. 2006; 25(11): 635–640.
  67. Hahn T, Drese KS, O'Sullivan CK. Microsystem for isolation of fetal DNA from maternal plasma by preparative size separation. Clin Chem. 2009; 55(12): 2144–2152.
  68. Raymond FL, Whittaker J, Jenkins L, et al. Molecular prenatal diagnosis: the impact of modern technologies. Prenat Diagn. 2010; 30(7): 674–681.
  69. Bellido ML, Radpour R, Lapaire O, et al. MALDI-TOF mass array analysis of RASSF1A and SERPINB5 methylation patterns in human placenta and plasma. Biol Reprod. 2010; 82(4): 745–750.
  70. Lun FMF, Chiu RWK, Chan KC, et al. Microfluidics digital PCR reveals a higher than expected fraction of fetal DNA in maternal plasma. Clin Chem. 2008; 54(10): 1664–1672.
  71. Voelkerding KV, Dames SA, Durtschi JD. Next-generation sequencing: from basic research to diagnostics. Clin Chem. 2009; 55(4): 641–658.



Journal of Transfusion Medicine